allogeneic anti-CD20 CAR T cells LUCAR-20S
Term · Oncology and biomedicine · MLC-T-ONC-009812
A preparation of donor-derived T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD20 (cluster of differentiation 20), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD20 CAR T cells LUCAR-20S specifically recognize and kill CD20-expressing tumor cells. The CD20 antigen, a non-glycosylated cell surface phosphoprotein, is a B-cell-specific cell surface antigen expressed in B-cell lineage malignancies.
| Identifier | MLC-T-ONC-009812 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | LUCAR-20S CAR-T cells |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-009812",
"term": "allogeneic anti-CD20 CAR T cells LUCAR-20S",
"field": "Oncology and biomedicine",
"definition": "A preparation of donor-derived T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD20 (cluster of differentiation 20), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD20 CAR T cells LUCAR-20S specifically recognize and kill CD20-expressing tumor cells. The CD20 antigen, a non-glycosylated cell surface phosphoprotein, is a B-cell-specific cell surface antigen expressed in B-cell lineage malignancies.",
"synonyms": [
"LUCAR-20S CAR-T cells"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/allogeneic-anti-cd20-car-t-cells-lucar-20s/"
}
Record 697 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.